PharmiWeb.com - Global Pharma News & Resources
25-Jun-2019

Macular Degeneration Treatment Market size to Garner more than US$ 11.4 Bn by 2026

The Global Macular Degeneration Treatment Market Size is expected to reach USD 11.4 Billion by 2026 and growing CAGR around 6.6 % during the forecast period.

The Global Macular Degeneration Treatment Market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2018 to 2026. The report offers of historic and future market scenario in terms of market value, share and critical developments taking place in the industry. Market size, forecast, trends of each country and region are studied in the report for the focus period of 2018 to 2026.

Request a Sample Copy of this Research Report athttps://www.acumenresearchandconsulting.com/request-sample/1203

Qualitative assessment tools such as PEST analysis, cost structure analysis and regulatory compliance for pharmaceutical products are offered in the report. The report also comprises Pipeline Analysis which helps understand the comprehensive forecast scenario of the market in terms of value and dynamics. The report analyses the recent drug approval trends and market dynamics such as drivers, restrains, and opportunities, industry trends and future outlook in the global Macular Degeneration Treatment Market.

Key Takeaways:

  • What is the market size in 2018 and the growth rate of the global Macular Degeneration Treatment Market?
  • What is the market drivers, restrains, opportunities governing the global Macular Degeneration Treatment Market?
  • Which is the largest and the fastest growing segments in the global Macular Degeneration Treatment Market?
  • Who are the key players operating in the market and their market position?
  • What is the pipeline scenario, drug pricing analysis and technological development in the market?

Market Players:

The report represents key players operating in the market along with its competitive landscape. The competitive landscape includes player positioning analysis, competitive matrix and market share analysis of the key players operating in the industry. The market attractive index highlights the most lucrative regional market to invest in the market. The Macular Degeneration Treatment Market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The key players of the market are GlaxoSmithKline plc, Novartis AG, Bayer AG, Neurotech Pharmaceuticals, Inc., Ophthotech Corporation, F. Hoffmann-La Roche Ltd., StemCells Inc., Pfizer, Inc., Sanofi, Santen Pharmaceuticals, Allergan, Inc., and Valeant Pharmaceuticals etc.

To Purchase this Premium Report at https://www.acumenresearchandconsulting.com/buy-now/0/1203

The Major Market Segments of GlobalMacular Degeneration Treatment Marketare as below:

Market Segmentation

Market By Disease Indication

  • Dry Age-related Macular Degeneration Treatment
  • Wet Age-related Macular Degeneration Treatment
  • Others

Market By Drug Class

  • Anti-vascular endothelial growth factor
  • Others

Market By End-user

  • Ambulatory Surgical Centers
  • Hospitals
  • Ophthalmic Clinics

Market By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Macular Degeneration Treatment
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Macular Degeneration Treatment Market By Disease Indication
1.2.2.1. Global Macular Degeneration Treatment Market Revenue and Growth Rate Comparison By Disease Indication (2015-2026)
1.2.2.2. Global Macular Degeneration Treatment Market Revenue Share By Disease Indication in 2017
1.2.2.3. Dry Age-related Macular Degeneration Treatment
1.2.2.4. Wet Age-related Macular Degeneration Treatment
1.2.2.5. Others
1.2.3. Macular Degeneration Treatment Market By Drug Class
1.2.3.1. Global Macular Degeneration Treatment Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.3.2. Anti-vascular endothelial growth factor
1.2.3.3. Others
1.2.4. Macular Degeneration Treatment Market By End Users
1.2.4.1. Global Macular Degeneration Treatment Market Revenue and Growth Rate Comparison By End Users (2015-2026)
1.2.4.2. Ambulatory Surgical Centers
1.2.4.3. Hospitals
1.2.4.4. Ophthalmic Clinics
1.2.5. Macular Degeneration Treatment Market by Geography
1.2.5.1. Global Macular Degeneration Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Hospitals Production Date of Global Macular Degeneration Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Macular Degeneration Treatment Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global Macular Degeneration Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Macular Degeneration Treatment Major Manufacturers in 2017

CHAPTER 4. MACULAR DEGENERATION TREATMENT MARKET BY DISEASE INDICATION

4.1. Global Macular Degeneration Treatment Revenue By Disease Indication
4.2. Dry Age-related Macular Degeneration Treatment
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Wet Age-related Macular Degeneration Treatment
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Others
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. MACULAR DEGENERATION TREATMENT MARKET BY DRUG CLASS

5.1. Global Macular Degeneration Treatment Revenue By Drug Class
5.2. Anti-vascular endothelial growth factor
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Others
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. Macular Degeneration Treatment MARKET BY END USERS

6.1. Global Macular Degeneration Treatment Revenue By End Users
6.2. Ambulatory Surgical Centers
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Hospitals
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Ophthalmic Clinics
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

7.1. North America Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Macular Degeneration Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. U.S.
7.3.1. U.S. Macular Degeneration Treatment Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

8.1. Europe Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Macular Degeneration Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

9.1. Asia-Pacific Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Macular Degeneration Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

10.1. Latin America Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Macular Degeneration Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

11.1. Middle East Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Macular Degeneration Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

12.1. Africa Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Macular Degeneration Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. GlaxoSmithKline plc
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Novartis AG
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Bayer AG
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Neurotech Pharmaceuticals, Inc.
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Ophthotech Corporation
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. F. Hoffmann-La Roche Ltd.
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. StemCells Inc.
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Pfizer, Inc.
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Sanofi
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Santen Pharmaceuticals
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies
13.11. Allergan, Inc.
13.11.1. Company Snapshot
13.11.2. Overview
13.11.3. Financial Overview
13.11.4. Type Portfolio
13.11.5. Key Developments
13.11.6. Strategies
13.12. Valeant Pharmaceuticals
13.12.1. Company Snapshot
13.12.2. Overview
13.12.3. Financial Overview
13.12.4. Type Portfolio
13.12.5. Key Developments
13.12.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

Buy this Premium Research Report at https://www.acumenresearchandconsulting.com/buy-now/0/1203

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 25-Jun-2019